Xcout IntelSign inSubscribe

Petros Pharmaceuticals, Inc.

PTPIPharmaceuticalsNew York City, United States

Petros Pharmaceuticals, Inc. is a pharmaceutical company dedicated to male health solutions. Their activities include both the commercialization and ongoing development of Stendra, a prescription PDE-5 inhibitor specifically designed for treating erectile dysfunction (ED). Furthermore, Petros is advancing H100, a proprietary topical formulation currently in development as a potential treatment for acute Peyronie's disease. The company's offerings also extend to a range of erectile dysfunction products, such as vacuum erection devices. Petros Pharmaceuticals, Inc. operates from its base in New York, New York.

Subscribe to see Petros Pharmaceuticals, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event

Petros Pharmaceuticals, Inc. at a glance

Petros Pharmaceuticals, Inc. is a pharmaceuticals company headquartered in New York City, United States. It is publicly listed (PTPI) with a market capitalisation of $169,489. Xcout tracks 11 named people at Petros Pharmaceuticals, Inc., including Fady Boctor (President & Chief Commercial Officer).

Industry
Pharmaceuticals
Headquarters
New York City, United States
Market cap
$169,489
Employees
18
Ticker
PTPI

Petros Pharmaceuticals, Inc. leadership

  • Fady BoctorPresident & Chief Commercial Officer
  • Robert WeinsteinChief Accounting Officer, Principal Financial Officer & Principal Accounting Officer
  • Joshua N. SilvermanExecutive Chairman of the Board
  • Mitch ArnoldVP of Finance, Chief Accounting Officer
  • Josh SilvermanVice-Chairman of the Board
  • Bruce BernsteinDirector

5 more named people on record for Petros Pharmaceuticals, Inc., with roles, board committees and tenure — see the full roster →

Petros Pharmaceuticals, Inc. funding rounds on record

Every round on record:

DateRoundAmountInvestors
Seed$125,000—

Some filings are not shown as funding rounds.

Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →

Petros Pharmaceuticals, Inc. competitors

A few of Petros Pharmaceuticals, Inc.'s closest competitors — see the full list of competitors and alternatives →

UNITED GUARDIAN INCUG · PharmaceuticalsHauppauge, United States
60% matchPublic

United-Guardian, Inc., operating both domestically and globally, specializes in the development, production, and distribution of a diverse range of cosmetic raw materials, pharmaceutical solutions, medical-grade lubricants, and proprietary industrial chemicals. Its extensive cosmetic ingredients catalog includes the LUBRAJEL line of water-based moisturizing and lubricating gel formulations, featuring variants such as LUBRAJEL NATURAL (derived from natural sources), LUBRAJEL MARINE, and LUBRASIL II SB (a silicone-infused LUBRAJEL formulation). Other key offerings in this category are LUBRAJEL II XD; B-122, a powdered lubricant suitable for pressed powders, eyeliners, blushes, and industrial uses; KLENSOFT, a surfactant for shampoos, shower gels, and makeup removers; and ORCHID COMPLEX, an oil-soluble base for skin creams, lotions, and cleansers. For medical applications, United-Guardian provides lubricants like LUBRAJEL RR and RC, which are water-based gels specifically designed for urinary catheters. LUBRAJEL MG serves to lubricate urinary catheters, pre-lubricated enema tips, and other medical devices. The company also offers LUBRAJEL LC and LUBRAJEL FA, specialized LUBRAJEL formulations tailored for oral care, alongside LUBRAJEL FLUID for lubricating various water-soluble products. The pharmaceutical portfolio features RENACIDIN, a prescription medication for preventing and dissolving calcifications in urethral catheters and the urinary bladder. Also included is CLORPACTIN WCS-90, an antimicrobial agent effective against infections in the urinary bladder, localized peritoneal infections, and infections affecting the eyes, ears, nose, throat, and sinuses. Industrial products comprise DESELEX, a sequestering and chelating agent vital for detergent manufacturing, and THOROCLENS, a powerful chlorine-based industrial cleaning solution. The firm also dedicates resources to research and development, primarily focusing on advancing cosmetic ingredients. Products are brought to market through a robust network of marketing partners, distributors, and wholesalers. Established in 1942, United-Guardian maintains its headquarters in Hauppauge, New York.

Market cap$32.9M
Employees24
UNITED GUARDIAN INC competitors & alternatives →
ADRバイオメディカルホールディングス3750 · BiotechnologyTokyo, Japan
60% matchPublic

Operating from its Tokyo headquarters, Cytori Cell Research Institute, Inc., established in 2004 (originally FRACTALE Corporation), specializes in the comprehensive research, development, production, and distribution of medical devices related to cell therapy throughout Japan. The company offers various cell therapy kits and continuously advances cellular treatment technologies through ongoing research and development. Its active development pipeline includes ECCI-50, designed for the treatment of male stress urinary incontinence and hepatic cirrhosis, and Cyt-006, formulated to prevent postoperative adhesion after primary rectal cancer surgery. Additionally, Cytori conducts extensive clinical trials and investigations into cell-based therapies for a wide array of conditions and applications, such as the repair of anterior cruciate ligaments and bones, burn scar remediation, chronic wound healing, critical limb ischemia, treatment of anal and Crohn's disease fistulas, and erectile dysfunction. Beyond its primary biotechnological focus, the company also participates in the real estate sector, encompassing investment, ownership, development, leasing, and management of properties and hotels, as well as providing real estate brokerage services.

Market cap$44.8M
Employees13
ADRバイオメディカルホールディングス competitors & alternatives →

Get Petros Pharmaceuticals, Inc.'s news by email

Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.

Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →

Share this card

Post the link and the card appears automatically — each network fetches the image itself.

Petros Pharmaceuticals, Inc. — share card preview

Instagram, TikTok and Slack canvases don't expand links — download the card as a PNG and post it as an image instead.

More on Petros Pharmaceuticals, Inc. in Xcout Intel

  • 11 named people with titles, LinkedIn and board committees
  • 1 funding round with the investors in each, and who they co-invest with
  • The full competitor set, tracking, exports and API access
Subscribe to Xcout Intel →